Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Zhang Website

Shuling Zhang, M.D., Ph.D.

Selected Publications

1)  Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Mol Oncol. 8: 261-72, 2014.
[Journal]
2)  Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.
A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.
J. Immunol. Methods. 390: 52-62, 2013.
[Journal]
3)  Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.
B cell-specific deficiencies in mTOR limit humoral immune responses.
J. Immunol. 191: 1692-703, 2013.
[Journal]
4)  Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T.
Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.
Cell Rep. 4: 913-20, 2013.
[Journal]
5)  Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA.
Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.
Blood. 117: 1228-38, 2011.
[Journal]
6)  Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, Gilfillan AM.
mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.
Blood. 118: 6803-13, 2011.
[Journal]
7)  Zhang K, Kagan D, DuBois W, Robinson R, Bliskovsky V, Vass WC, Zhang S, Mock BA.
Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.
Blood. 114: 2952-60, 2009.
[Journal]
8)  Mock B, Zhang S, Ramsay E, Bliskovsky V, Zhang K, Shi W, DuBois W.
Strategies for dissection complex traits associated with cancer: lessons from plasma cell tumors. In: AACR Education Book 2005.
Philadelphia: AACR; 2005. p. 273-276 [Book Chapter]
9)  Richardson JY, Ottolini MG, Pletneva L, Boukhvalova M, Zhang S, Vogel SN, Prince GA, Blanco JC.
Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy.
J. Immunol. 174: 4356-64, 2005.
[Journal]
10)  Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, Arditi M, Gallin JI, Vogel SN.
Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections.
J. Exp. Med. 198: 521-31, 2003.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 7/11/2014.